1887

Abstract

Dengue virus (DENV) has four distinct serotypes, DENV-1–4, with four to six genotypes in each serotype. The World Health Organization recommends tetravalent formulations including one genotype of each serotype as safe and effective dengue vaccines. Here, we investigated the impact of genotype on the neutralizing antibody responses to DENV-1 in humans. Convalescent sera collected from patients with primary infection of DENV-1 were examined for neutralizing antibody against single-round infectious particles of the five DENV-1 genotypes (GI–GV). In both GI- and GIV-infected patients, their neutralizing antibody titres against the five genotypes were similar, differing ≤4-fold from the homogenotypic responses. The enhancing activities against the five genotypes were also similar in these sera. Thus, the genotype strains of DENV-1 showed no significant antigenic differences in these patients, suggesting that GI- or GIV-derived vaccine antigens should induce equivalent levels of neutralizing antibodies against all DENV-1 genotypes.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000669
2017-02-24
2019-10-15
Loading full text...

Full text loading...

/deliver/fulltext/jgv/98/2/166.html?itemId=/content/journal/jgv/10.1099/jgv.0.000669&mimeType=html&fmt=ahah

References

  1. Halstead SB. Dengue. The Lancet 2007;370:1644–1652 [CrossRef]
    [Google Scholar]
  2. Guzman MG, Harris E. Dengue. The Lancet 2015;385:453–465 [CrossRef][PubMed]
    [Google Scholar]
  3. Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis 2012;6:e1760 [CrossRef][PubMed]
    [Google Scholar]
  4. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW et al. The global distribution and burden of dengue. Nature 2013;496:504–507 [CrossRef][PubMed]
    [Google Scholar]
  5. Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015;373:1195–1206 [CrossRef][PubMed]
    [Google Scholar]
  6. World Health Organization. 2015; Immunization, vaccines and biologicals. questions and answers on dengue vaccines. www.who.int/immunization/research/development/dengue_q_and_a/en/ accessed 15 September 2016
  7. World Health Organization 2009; Dengue guidelines for diagnosis, treatment, prevention and control. http://apps.who.int/iris/bitstream/10665/44188/1/9789241547871_eng.pdf accessed 15 September 2016
  8. Huisman W, Martina BE, Rimmelzwaan GF, Gruters RA, Osterhaus AD. Vaccine-induced enhancement of viral infections. Vaccine 2009;27:505–512 [CrossRef][PubMed]
    [Google Scholar]
  9. Halstead SB, O'Rourke EJ. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 1977;265:739–741 [CrossRef][PubMed]
    [Google Scholar]
  10. Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003;60:421–467[PubMed][CrossRef]
    [Google Scholar]
  11. Pierson TC, Diamond MS. Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med 2008;10:e12 [CrossRef][PubMed]
    [Google Scholar]
  12. Weaver SC, Vasilakis N. Molecular evolution of dengue viruses: contributions of phylogenetics to understanding the history and epidemiology of the preeminent arboviral disease. Infect Genet Evol 2009;9:523–540 [CrossRef][PubMed]
    [Google Scholar]
  13. Murphy BR, Whitehead SS. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 2011;29:587–619 [CrossRef][PubMed]
    [Google Scholar]
  14. Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA et al. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 2010;6:e1000823 [CrossRef][PubMed]
    [Google Scholar]
  15. Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA et al. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol 2010;84:9227–9239 [CrossRef][PubMed]
    [Google Scholar]
  16. Brien JD, Austin SK, Sukupolvi-Petty S, O'Brien KM, Johnson S et al. Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol 2010;84:10630–10643 [CrossRef][PubMed]
    [Google Scholar]
  17. Chen S. The origin of dengue viruses caused the DF outbreak in Guangdong province, China, in 2006. Infect Genet Evol 2011;11:1183–1187 [CrossRef][PubMed]
    [Google Scholar]
  18. Tissera HA, Ooi EE, Gubler DJ, Tan Y, Logendra B et al. New dengue virus type 1 genotype in Colombo, Sri Lanka. Emerg Infect Dis 2011;17:2053–2055 [CrossRef][PubMed]
    [Google Scholar]
  19. Messer WB, Gubler DJ, Harris E, Sivananthan K, de Silva AM. Emergence and global spread of a dengue serotype 3, subtype III virus. Emerg Infect Dis 2003;9:800–809 [CrossRef][PubMed]
    [Google Scholar]
  20. Yamanaka A, Mulyatno KC, Susilowati H, Hendrianto E, Ginting AP et al. Displacement of the predominant dengue virus from type 2 to type 1 with a subsequent genotype shift from IV to I in Surabaya, Indonesia 2008–2010. PLoS One 2011;6:e27322 [CrossRef][PubMed]
    [Google Scholar]
  21. Villabona-Arenas CJ, Zanotto PM. Worldwide spread of dengue virus type 1. PLoS One 2013;8:e62649 [CrossRef][PubMed]
    [Google Scholar]
  22. Konishi E, Kosugi S, Imoto J. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 2006;24:2200–2207 [CrossRef][PubMed]
    [Google Scholar]
  23. Suzuki R, Ishikawa T, Konishi E, Matsuda M, Watashi K et al. Production of single-round infectious chimeric flaviviruses with DNA-based Japanese encephalitis virus replicon. J Gen Virol 2014;95:60–65 [CrossRef][PubMed]
    [Google Scholar]
  24. Yamanaka A, Suzuki R, Konishi E. Evaluation of single-round infectious, chimeric dengue type 1 virus as an antigen for dengue functional antibody assays. Vaccine 2014;32:4289–4295 [CrossRef][PubMed]
    [Google Scholar]
  25. Salje H, Rodríguez-Barraquer I, Rainwater-Lovett K, Nisalak A, Thaisomboonsuk B et al. Variability in dengue titer estimates from plaque reduction neutralization tests poses a challenge to epidemiological studies and vaccine development. PLoS Negl Trop Dis 2014;8:e2952 [CrossRef][PubMed]
    [Google Scholar]
  26. Konishi E, Tabuchi Y, Yamanaka A. A simple assay system for infection-enhancing and -neutralizing antibodies to dengue type 2 virus using layers of semi-adherent K562 cells. J Virol Methods 2010;163:360–367 [CrossRef][PubMed]
    [Google Scholar]
  27. Verschueren J, Cnops L, van Esbroeck M. Twelve years of dengue surveillance in Belgian travellers and significant increases in the number of cases in 2010 and 2013. Clin Microbiol Infect 2015;21:867–872 [CrossRef][PubMed]
    [Google Scholar]
  28. Kotaki T, Yamanaka A, Mulyatno KC, Churrotin S, Labiqah A et al. Continuous dengue type 1 virus genotype shifts followed by co-circulation, clade shifts and subsequent disappearance in Surabaya, Indonesia, 2008–2013. Infect Genet Evol 2014;28:48–54 [CrossRef][PubMed]
    [Google Scholar]
  29. Ministry of Economy, Trade and Industry of Japan 2010; Security export control policy. www.meti.go.jp/policy/anpo/englishpage.html accessed 15 September 2016
  30. Convention on Biological Diversity 2010; The Nagoya protocol on access and benefit-sharing. www.cbd.int/abs/ accessed 15 September 2016
  31. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014;384:1358–1365 [CrossRef][PubMed]
    [Google Scholar]
  32. Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015;372:113–123 [CrossRef][PubMed]
    [Google Scholar]
  33. Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM et al. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J Infect Dis 2015;212:702–710 [CrossRef][PubMed]
    [Google Scholar]
  34. Martinez LJ, Lin L, Blaylock JM, Lyons AG, Bauer KM et al. Safety and immunogenicity of a dengue virus serotype-1 purified-inactivated vaccine: results of a phase 1 clinical trial. Am J Trop Med Hyg 2015;93:454–460 [CrossRef][PubMed]
    [Google Scholar]
  35. Porter KR, Ewing D, Chen L, Wu SJ, Hayes CG et al. Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine. Vaccine 2012;30:336–341 [CrossRef][PubMed]
    [Google Scholar]
  36. Wahala WM, Silva AM. The human antibody response to dengue virus infection. Viruses 2011;3:2374–2395 [CrossRef][PubMed]
    [Google Scholar]
  37. Williams KL, Wahala WM, Orozco S, de Silva AM, Harris E. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology 2012;429:12–20 [CrossRef][PubMed]
    [Google Scholar]
  38. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci USA 2012;109:7439–7444 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000669
Loading
/content/journal/jgv/10.1099/jgv.0.000669
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error